GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (OTCPK:STAB) » Definitions » Preferred Stock

Statera BioPharma (Statera BioPharma) Preferred Stock : $0.00 Mil (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Statera BioPharma's preferred stock for the quarter that ended in Sep. 2022 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Statera BioPharma's Enterprise Value for the quarter that ended in Sep. 2022 was $13.24 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Statera BioPharma's Book Value per Share for the quarter that ended in Sep. 2022 was $-0.20.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Statera BioPharma's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-0.07.


Statera BioPharma Preferred Stock Historical Data

The historical data trend for Statera BioPharma's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Preferred Stock Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Preferred Stock
- - -

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Statera BioPharma Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Statera BioPharma  (OTCPK:STAB) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Statera BioPharma's Enterprise Value for the quarter that ended in Sep. 2022 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Statera BioPharma's Book Value per Share for the quarter that ended in Sep. 2022 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Statera BioPharma's Earnings per Share (Diluted) (EPS) for the three months ended in Sep. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Statera BioPharma Preferred Stock Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Statera BioPharma (Statera BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.
Executives
Satishchandran Chandrasekhar director 167 CARMELA COURT, JUPITER FL 33478
Taunia Markvicka director, officer: Chief Operating Officer 2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Robert Buckheit officer: Chief Technology Officer C/O CYTOCOM INC., 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Mcavoy Cozette M. officer: Chief Legal Officer 2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Michael K Handley director, officer: President and CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Clifford Selsky officer: Chief Medical Officer 2537 RESEARCH BOULERVARD, SUITE 201, FORT COLLINS CO 80526
Peter Aronstam officer: Chief Financial Officer 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Steve K Barbarick director TRACTOR SUPPLY COMPANY, 5401 VIRGINIA WAY, BRENTWOOD TN 37027
Christopher Zosh officer: Vice President of Finance C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin director 73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo officer: Principal Financial Officer 73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin director 73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy director 73 HIGH STREET, BUFFALO NY 14203
Lea Verny director 73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev director 73 HIGH STREET, BUFFALO NY 14203

Statera BioPharma (Statera BioPharma) Headlines

From GuruFocus

Statera Biopharma, Inc. Files Form 12b-25

By GuruFocusNews GuruFocusNews 03-31-2022